Press Releases

Press Releases

2016  |  2015  |  2014

JAMA Looks to SCCA Physicians to Address Future of Immunotherapy


Today’s issue of The Journal of the American Medical Association (JAMA) features an editorial by two Seattle Cancer Care Alliance (SCCA) medical oncologists who specialize in melanoma: Dr. Shailender Bhatia and Dr. John Thompson. Their editorial addresses the state of immunotherapy drugs, specifically PD-1 blockade, in the treatment of melanoma. Both physicians have been on the front lines of immunotherapy research, including leading early trials of pembrolizumab, the drug used to treat President Jimmy Carter’s melanoma.   

NEW 04-19-2016 JAMA-Editorial-2016.pdf (124kb)

SCCA Honored for Commitment to LGBT Patients, Families & Staff


Seattle Cancer Care Alliance (SCCA) has been recognized as a “Leader in LGBT Healthcare Equality” by the Human Rights Campaign (HRC) Foundation, the educational arm of the country’s largest lesbian, gay, bisexual and transgender (LGBT) civil rights organization. The honor is awarded to healthcare facilities that meet the HRC’s four core LGBT-inclusive benchmarks evaluating organizational policies and practices related to LGBT patients, families and employees.   

NEW 04-12-2016 SCCA -HRC-Leader-In-LGBT.pdf (106kb)

Seattle Cancer Care Alliance Named 150 Great Places to Work in Healthcare


Seattle Cancer Care Alliance (SCCA) has been named one of “150 Great Places to Work in Healthcare” by Becker’s Healthcare. This is the first time SCCA has been named to the list, which has been published every year since 2011.  

NEW 04-07-2016 Beckers-Award-150-Best-Places-to-Work.pdf (108kb)

SCCA To Debut New Ads During Local Super Bowl Broadcast


Following the success of its recent brand relaunch, Seattle Cancer Care Alliance (SCCA) will kick off its 2016 advertising campaign with a television commercial debuting during the local broadcast of the Super Bowl on Sunday, Feb. 7, on CBS affiliate KIRO-TV.  

02-08-2016 SCCA-Debuts-TV-Ads.pdf (5935kb)

New global initiative for breast cancer has roots in Seattle


SEATTLE – (Feb. 3, 2016) – World Cancer Day—Thursday, Feb. 4, 2016—is the web launch of a new global campaign to reduce disparities in breast cancer outcomes for 2.5 million women by 2025. Called Breast Cancer Initiative 2.5 (BCI2.5), the campaign is spearheaded by two internationally renowned breast cancer physicians based in Seattle, Washington: Julie R. Gralow, M.D. and Benjamin O. Anderson, M.D. Both physicians are part of Seattle Cancer Care Alliance and its partners, Fred Hutchinson Cancer Research Center and UW Medicine. To kick-off the campaign on World Cancer Day, BCI2.5 is launching its website, www.bci25.org, which will serve as a platform and resource for policy makers, clinicians and health advocates from across the world.  

02-08-2016 BCI2.5-Press-Release.pdf (118kb)

Seattle Magazine Names 33 Seattle Cancer Care Alliance Top Doctors


The February 2016 issue of Seattle Magazine features 33 Seattle Cancer Care Alliance (SCCA) oncologists and specialists as Top Doctors. Physicians from SCCA’s three world-class partner organizations—Fred Hutchinson Cancer Research Center, Seattle Children’s and UW Medicine—appear prominently throughout the list.  

02-08-2016 Seattle-Magazine -SCCA-2016-Top-Docs.pdf (133kb)

Seattle Cancer Care Alliance at EvergreenHealth Welcomes Oncologist Dr. Eric Dean


Seattle Cancer Care Alliance (SCCA) has hired board-certified, medical oncologist Eric Dean, M.D., who will be based at the SCCA community site EvergreenHealth in Kirkland. He is also a newly appointed faculty member of the University of Washington School of Medicine.   

01-27-2016 Eric-Dean-MD-Joins-SCCA.pdf (101kb)

Seattle Cancer Care Alliance M.D. Receives National Research Grant


Seattle Cancer Care Alliance researcher and oncologist, Ajay Gopal, M.D., has received one of five national research grants awarded by the National Comprehensive Cancer Network® (NCCN®) to evaluate and define the pre-clinical and clinical effectiveness of enzalutamide in mantle cell lymphoma and endometrial, hepatocellular and prostate cancers. Dr. Gopal’s study focuses on “Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Phase II Trial of Enzalutamide.”  

01-22-2016 Ajay-Gopal-MD-Recipient-National-Grant-2016.pdf (114kb)


2016  |  2015  |  2014